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Thromboelastography Profiles of Hemophilia A patients on Emicizumab

1 Wayne

Daniel VanZweden1, Charity Stadler RN, BSN2, Meera Chitlur1,2 MD
State University, Detroit, MI, USA; 2Carman and Ann Adams Department of Pediatrics, Children’s Hospital of Michigan, Detroit, MI, USA

BACKGROUND
Hemophilia A is an inherited bleeding disorder caused by a deficiency of
Factor VIII (FVIII) of the coagulation cascade.
Emicizumab is a new monoclonal antibody, with Factor VIII mimetic
activity, has been found to be highly effective for bleed prevention and
therefore has been approved for treatment patients with Hemophilia A1.
Unlike FVIII prophylaxis which is associated with peaks and troughs and
is administered intravenously, Emicizumab is associated with a steady
state correction of coagulation following four weekly subcutaneous,
loading doses.
Traditional FVIII replacement therapy is monitored using the APTT assay.
The APTT in patients on Emicizumab is artificially shortened, and as
such is inaccurate and cannot be used for monitoring2.
Breakthrough bleeding, although very uncommon, may occur in patients
on Emicizumab3.
Thromboelastography (TEG) is a novel, global coagulation assay that
measures coagulation in whole blood by measuring changes in
viscosity. Few publications have attempted to determine the effect of
Emicizumab on TEG4.
This study describes the Tissue Factor activated TEG (TF-TEG)
characteristics in twenty-two patients taking Emicizumab, three of
whom experienced breakthrough bleeding.

OBJECTIVES
The purpose of this study was to determine the sensitivity of TF-TEG
parameters (alpha angle, clot formation time, reaction time, or
maximum amplitude) for predicting breakthrough bleeding.
If a sensitive parameter to predict bleeding can be identified, the eventual
goal is to use the results of this study to promote the widespread use of
TF-TEG to monitor treatment.

METHODS

RESULTS

A retrospective chart-review was conducted on patients treated with
Emicizumab at Children’s Hospital of Michigan from 2016 until 2020,
following Institutional review board approval.
Medical charts were reviewed to obtain bleeding history at each of the visits
and laboratory data.
TEG’s were performed using previously described method with low dose
tissue factor as an activator5.
TEG parameters (alpha angle, maximum amplitude (MA), reaction time (R),
and clot formation time (K)) and APTT were included in the data
collected.

Twenty-two patients were included in the study based on the availability of
laboratory data and bleeding history.
The average age of patients was 11 years old with a range of 19.7 years,
and the average time since the start of Emicizumab was 45 weeks (>6
months).
Five patients had breakthrough bleeding with trauma, while two exhibited
spontaneous breakthrough bleeding
Table 1 shows the means of the TEG parameters in patients on the study.
Patients exhibiting breakthrough bleeding showed a 24% increase in K
time, as well as a 25% increase in R time suggestive of delayed clot
formation compared to those without a bleeding phenotype, making these
parameters of the TF-TEG assay the most desirable to use in predicting
which patients may have breakthrough bleeding.

K (1-2 min)
R time (3-8
min)

Average
TEG profile
on factor
(n=19)

2.7
8.8

Average on
Emecizumab
(no
breakthrough
bleeding)
(n=25)

Average of
breakthrough
bleeding
episodes (n=7)

2.3
7.5

2.9
9.3

21 sec is the lower limit of measurement of the APTT in the laboratory and
was used as the arbitrary cutoff to classify the APTT as elevated, or normal.
Using the bleeding descriptions and the reported APTT, the reported APTT
was classified as a true positive, true negative, false positive, or false
negative.
Twenty-six APTT data points were collected and analyzed, giving an overall
sensitivity of 29%, and a specificity of 89%.

CONCLUSIONS
This is the first study to utilize the TEG to determine its utility to predict
breakthrough bleeding in patients on Emicizumab

RESULTS

TF-TEG
parameter
(normal
range)

APTT was divided into two categories, those greater than 21sec, and those
less than 21sec, as Emicizumab has been shown to shorten the assay.

Percent
increased or
decreased
(breakthrough
bleeds vs no
breakthrough
bleeds)
+24%
+25%

Currently, APTT is used in many hospitals without access to TEG
APTT’s low sensitivity of 29% makes it undesirable as an assay to predict
breakthrough bleeding, although the high specificity of 89% may confirm
its ability to identify patients who will not exhibit breakthrough bleeding.
The results of this study show that TEG may be helpful in assessing the risk
for breakthrough bleeding in patients receiving Emicizumab.

LIMITATIONS
This study has several limitations, including the fact that it is a very small
study on a small group of patients.
The TEG was performed at our center using a modified approach of low
dose tissue factor which may have increased the sensitivity of the assay.
Further data are warranted to determine if kaolin (the standardized assay)
may be used with the same sensitivity.
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